NovoCure Limited (NASDAQ:NVCR) Receives $26.93 Consensus PT from Analysts

NovoCure Limited (NASDAQ:NVCR) has earned an average recommendation of “Hold” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.9286.

A number of equities research analysts have recently commented on NVCR shares. Wedbush reaffirmed a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a report on Thursday, January 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. HC Wainwright boosted their price target on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Evercore set a $20.00 price objective on NovoCure in a research report on Monday, January 5th.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

NovoCure Stock Performance

Shares of NovoCure stock opened at $13.04 on Friday. The firm’s fifty day simple moving average is $12.74 and its 200-day simple moving average is $12.72. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.69 and a beta of 0.71. NovoCure has a 12 month low of $9.82 and a 12 month high of $21.55. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 2.71.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The firm had revenue of $174.35 million during the quarter, compared to analysts’ expectations of $174.40 million. During the same quarter in the prior year, the business earned ($0.61) EPS. NovoCure’s quarterly revenue was up 8.2% compared to the same quarter last year. As a group, equities analysts forecast that NovoCure will post -1.3 earnings per share for the current year.

Insider Buying and Selling at NovoCure

In related news, COO Mukund Paravasthu sold 43,246 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $13.77, for a total transaction of $595,497.42. Following the completion of the sale, the chief operating officer directly owned 72,832 shares of the company’s stock, valued at $1,002,896.64. This trade represents a 37.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman William F. Doyle sold 71,887 shares of NovoCure stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total transaction of $933,093.26. Following the completion of the transaction, the chairman owned 328,397 shares in the company, valued at approximately $4,262,593.06. This trade represents a 17.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 140,041 shares of company stock valued at $1,860,116. Corporate insiders own 5.52% of the company’s stock.

Institutional Trading of NovoCure

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kera Capital Partners Inc. raised its holdings in NovoCure by 84.4% during the fourth quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 9,015 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in NovoCure by 178.0% in the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock valued at $1,259,000 after purchasing an additional 62,341 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in NovoCure by 14.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after purchasing an additional 4,124 shares during the period. Empowered Funds LLC acquired a new position in NovoCure during the 4th quarter worth approximately $33,000. Finally, XTX Topco Ltd raised its stake in shares of NovoCure by 159.2% during the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after buying an additional 36,111 shares in the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.